Sugi Predict

Sugi Predict / Compounds / SCHEMBL4274353

SCHEMBL4274353

SCHEMBL4274353

CNc1ncc2cc(-c3ccc(F)c(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)c(=O)n(C)c2n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRAF P15056 5/20 0.55
▸ RAF1 P04049 3/20 0.55
▸ KDR P35968 10/20 0.49
▸ KRAS P01116 2/20 0.49
▸ SIK2 Q9H0K1 2/20 0.47
▸ SIK1 P57059 1/20 0.47
▸ SIK3 Q9Y2K2 1/20 0.47
▸ EGFR P00533 1/20 0.46
▸ FGFR1 P11362 1/20 0.46
▸ SRC P12931 1/20 0.46
▸ SYK P43405 1/20 0.45
▸ MAPK14 Q16539 7/20 0.44
▸ LCK P06239 5/20 0.44
▸ JAK3 P52333 5/20 0.44
▸ PDGFRB P09619 2/20 0.44
▸ MAP2K2 P36507 1/20 0.44
▸ MAP2K1 Q02750 1/20 0.44
▸ STK4 Q13043 1/20 0.43
▸ STK3 Q13188 1/20 0.43
▸ STK26 Q9P289 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5057372 0.92 LCK (0.55) BRAFRAF1KDRKRASSIK2
SCHEMBL5062959 0.90 BRAF (0.51) BRAFRAF1KDRKRASSIK2
SCHEMBL5057671 0.89 SIK2 (0.53) BRAFRAF1KDRKRASSIK2
SCHEMBL5065390 0.89 BRAF (0.70) BRAFRAF1KDRKRASSIK2
SCHEMBL5057367 0.89 KDR (0.47) BRAFRAF1KDRKRASSIK2
SCHEMBL5061780 0.87 BRAF (0.54) BRAFRAF1KDRKRASSIK2
SCHEMBL5062852 0.86 BRAF (0.52) BRAFRAF1KDRKRASSIK2
SCHEMBL5062847 0.86 BRAF (0.58) BRAFRAF1KDRKRASSIK2
SCHEMBL4425430 0.86 SRC (0.53) BRAFRAF1KDRKRASSIK2
SCHEMBL5061443 0.86 BRAF (0.55) BRAFRAF1KDRKRASSIK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 — — US claimed
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-11-15 — — US disclosed
US-8188113-B2 For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies DECIPHERA PHARMACEUTICALS, INC. (US) 2012-05-29 — — US disclosed
EP-2063897-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2009-06-03 — — EP disclosed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 — — US disclosed
WO-2008034008-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC. (US) 2008-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES BRAF, PRKDC, RAF1 BRAF 1/4885RAF1 3/4885KDR 500/4885
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 BRAF 1/4885RAF1 3/4885KDR 500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.